10011236  C-Reactive Protein (human) EIA Kit

CRP (human) EIA Kit

Cayman offers free EIA analysis tools you may find helpful.

Let Cayman analyze your samples for you. See EIA Service for details and availability.

For active pharmaceutical ingredients (APIs) related to C-Reactive Protein (human) EIA Kit, see Cayman Pharma

Limit of detection: 46.9 pg/ml · C-Reactive Protein (CRP) is a 224 amino acid protein that is synthesized primarily by hepatocytes, and to a lesser extent adipocytes. CRP plasma levels increase ~1,000-fold in response to acute and chronic inflammatory conditions, making it a useful gauge of inflammation in a wide range of physiological and pathological conditions.1 Normal levels of serum CRP (0.64 µg/ml) do not differ between healthy adult men and women, but tend to increase slightly with age.2 High plasma CRP concentrations (>3 µg/ml) are associated with an increased risk for atherosclerosis.3 CRP has been implicated as a contributor to atherogenesis by modulating endothelial function, stimulating coagulation, inducing the expression of ICAM-1, VCAM-1, and E-selectin, mediating uptake of LDL into macrophages, and destabilizing plaques.1,4,5,6,7,8,9 In addition, CRP can bind in a calcium-dependent manner to phosphocholine on microbes, act as a ligand for specific receptors on phagocytic leukocytes, mediate activation of monocytes and macrophages via IL-6, TNF-α and other cytokines, and assist in the complement pathway.1,10,11,12 Cayman’s CRP (human) EIA Kit is an immunometric assay which can be used to measure CRP in plasma without prior sample purification. The standard curve spans the range of 0-3,000 pg/ml with a limit of detection of approximately 50 pg/ml.

1  Volanakis, J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 38 189-197 (2001). 2  Macy, E.M., Hayes, T.E., Tracy, R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43(1) 52-58 (1997). 3  Ridker, P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 363-369 (2003). 4  Pasceri, V., Willerson, J.T., Yeh, E.T.H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 2165-2168 (2000). 5  Tracy, R.P. Inflammation in cardiovascular disease cart, horse, or both?. Circulation 97 2000-2002 (1998). 6  Fichtlscherer, S., Rosenberger, G., Walter, D.H., et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102 1000-1006 (2000). 7  Zwaka, T.P., Hombach, V., Torzewski, J. C-reactive protein-mediated low density lipoprotein uptake by macrophages. Implications for atherosclerosis. Circulation 103 1194-1197 (2001). 8  Howitz, K.T., Bitterman, K.J., Cohen, H.Y., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 191-196 (2003). 9  de Ferranti, S., Rifai, N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 317 1-15 (2002). 10  Marnell, L.L., Mold, C., Volzer, M.A., et al. C-reactive protein binds to FcgRI in transfected COS cells. J Immunol 155 2185-2193 (1995). 11  Szalai, A.J., van Ginkel, F.W., Wang, Y., et al. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J Immunol 165 1030-1035 (2000). 12  Ganapathi, M.K., Rzewnicki, D., Samols, D., et al. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in HEP 3B cells. J Immunol 147(4) 1261-1265 (1991).

	Download Kit Booklet 570 Kb PDF
	Download Material Safety Data Sheet (MSDS) 361 Kb PDF

Many of our kits require a source of UltraPure Water. If you do not have a source it is available for purchase from Cayman Chemical. Please check the Additional Items Required section of this kit booklet to verify if Ultra Pure Water is needed. Please note that the 480 well kits are supplied with a single 500 dtn vial of tracer and antiserum that must be used within the stated time following reconstitution. Please see the individual kit booklets for these details or contact techserv@caymanchem.com.